Understanding cultural and regulatory differences in BRIC countries could help multinational CROs move to the forefront of clinical development and compete with local CROs for drug trial contracts, say researchers.
The past few days have seen a string of announcements from contract research organisations (CROs) which indicate that their appetite for international expansion and development remains unsated.
Quintiles Transnational Corp has announced an expansion of its operations in Singapore in order to meet what it described as “surging demand” in the Asia-Pacific region.